Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05441852 · ClinicalTrials.gov registry record
A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG)
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 1,151
- Enrollment target
NCT05441852: Completed study, sponsored by Mayo Clinic.
NCT05441852 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 1,151 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05441852 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 1,151 participants
- Enrollment target
Study Summary
The purpose of this study is to validate the real-world performance of a previously developed Artificial Intelligence - Electrocardiogram (AI-ECG) algorithm for identification of hyperkalemia with a six-lead mobile-enhanced device .
Primary Outcome
Understanding model's ability to predict hyperkalemia as determined by the area under the receiver operating characteristic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,151 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2023-07-07 |
What the finished NCT05441852 record still lists
NCT05441852 is an observational study that tracks outcomes without assigning an intervention. Its 1,151 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05441852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05441852 about?
NCT05441852 is a clinical study titled "A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG)". The purpose of this study is to validate the real-world performance of a previously developed Artificial Intelligence - Electrocardiogram (AI-ECG) algorithm for identification of hyperkalemia with a six-lead mobile-enhanced device .
What is the current status of trial NCT05441852?
This trial is currently completed. The enrollment target is 1,151 participants. The study started on 2022-03-31. Estimated completion is 2023-07-07.
Who is sponsoring clinical trial NCT05441852?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05564026 · 1,151 participants
Molecular Epidemiology of Pediatric Germ Cell Tumors
- NCT04474301 · 1,152 participants
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI